billS1410Thursday, April 10, 2025Analyzed

Find It Early Act

Neutral
Impact4/10

Summary

The 'Find It Early Act' (S.1410) aims to mandate no cost-sharing for additional breast screenings for high-risk individuals, potentially increasing demand for advanced diagnostic services. The bill is in early stages, having been introduced and referred to committee on April 10, 2025. While it could benefit medical imaging and diagnostic companies, it also increases payout obligations for insurance companies.

Key Takeaways

  • 1.The 'Find It Early Act' (S.1410) mandates no cost-sharing for additional breast screenings for high-risk individuals.
  • 2.This bill would increase demand for advanced diagnostic services, benefiting medical imaging and diagnostic lab companies.
  • 3.Insurance companies would incur higher payout obligations due to the no cost-sharing requirement.
  • 4.The bill is in the early stages, having been introduced and referred to committee in April 2025, with no subsequent legislative action.

Market Implications

If enacted, the 'Find It Early Act' would structurally increase revenue for companies providing breast cancer diagnostic services and equipment, such as GE HealthCare Technologies Inc. ($GEHC), Hologic, Inc. ($HOLX), Labcorp Holdings Inc. ($LH), and Quest Diagnostics Incorporated ($DGX), due to increased utilization of advanced screenings. Conversely, health insurance providers like UnitedHealth Group Incorporated ($UNH) would face increased costs from covering these screenings without patient cost-sharing. Current market movements for these tickers are not directly linked to this early-stage bill.

Full Analysis

The 'Find It Early Act' (S.1410) was introduced in the Senate on April 10, 2025, and subsequently referred to the Committee on Health, Education, Labor, and Pensions. This bill proposes to amend the Public Health Service Act to require health coverage with no cost-sharing for additional breast screenings for individuals at increased risk of breast cancer or with dense breast tissue. This includes various imaging technologies such as 2D/3D mammograms, breast ultrasounds, breast MRI, and molecular breast imaging. This bill does not authorize or appropriate a specific funding amount. Instead, it mandates a change in health insurance coverage, shifting the cost burden for these screenings from the patient to the insurance provider. This structural change would increase the volume of advanced diagnostic services utilized by eligible individuals, as the financial barrier of co-pays and deductibles would be removed. The money trail would flow from insurance companies to diagnostic service providers and medical imaging equipment manufacturers. Structural winners, if this bill were to become law, would include companies involved in breast cancer diagnostics and medical imaging. This includes GE HealthCare Technologies Inc. ($GEHC), which manufactures medical imaging equipment, Hologic, Inc. ($HOLX), a key player in breast health technology, and diagnostic labs like Labcorp Holdings Inc. ($LH) and Quest Diagnostics Incorporated ($DGX) that process these screenings. Conversely, insurance companies such as UnitedHealth Group Incorporated ($UNH) would face increased payout obligations due to the mandated no cost-sharing provision. The bill is currently in the early stages of the legislative process, with no further action since its referral to committee in April 2025. Looking at recent market data, Hologic, Inc. ($HOLX) is trading near its 52-week high at $76.01, showing a +0.61% 7-day change and +0.34% 30-day change. Labcorp Holdings Inc. ($LH) has seen a +4.12% 7-day change, currently at $274.46. GE HealthCare Technologies Inc. ($GEHC) is at $70.4, with a +2.37% 7-day change but a -8.7% 30-day change. Quest Diagnostics Incorporated ($DGX) is at $198.96, with a +0.91% 7-day change. UnitedHealth Group Incorporated ($UNH) is at $281.36, with a +7.48% 7-day change but a -2.57% 30-day change. These movements are not directly attributable to the 'Find It Early Act' given its early legislative stage. For this bill to progress, it must pass through the Committee on Health, Education, Labor, and Pensions, then be voted on by the full Senate, and subsequently pass through the House of Representatives before being sent to the President for signature. Given its introduction in April 2025 and no further action, it remains in the initial phase of the legislative process.

Market Impact Score

4/10
Minimal ImpactModerateMajor Market Event